Logo

DiaSorin

Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance

The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests. 

Decline in DiaSorin's Q2 MDx Revenues Offset by Strength in Immunodiagnostics

Non-COVID-19 immunodiagnostics revenues drove an otherwise strong quarter for DiaSorin with continued growth in North America and Europe and slow improvement in China.

In Brief This Week: HTG Molecular, Prenetics, DiaSorin, DermTech, NanoString Technologies, More

News items for the week of June 5, 2023

DiaSorin Q1 Revenues Fall 19 Percent on COVID Sales Decline

A 78 percent decline in COVID testing revenues was partially offset by revenue growth in its other diagnostics businesses.

DiaSorin 2022 Revenues Grow 10 Percent

For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million.

Mar 20, 2023

DiaSorin Gets FDA 510(k) for Molecular COVID-19/Flu Assay

Mar 3, 2023

In Brief This Week: DermTech, Applied BioCode, Devyser, DiaSorin, Cytek, Bio-Techne, GenScript, More

Feb 13, 2023

DiaSorin Selling Luminex Flow Cytometry Business to Cytek Biosciences for $46.5M

Nov 9, 2022

DiaSorin Gets FDA 510(k) Clearance for Molecular CMV Test

Oct 27, 2022

DiaSorin Q3 Revenues Dip 5 Percent as COVID-19 Test Sales Fall

Oct 5, 2022

DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument

Sep 14, 2022

DiaSorin Gains FDA 510(k) Clearance for COVID-19 PCR Test

Aug 3, 2022

DiaSorin Posts 32 Percent Jump in Q2 Revenues

May 20, 2022

Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19

May 6, 2022

DiaSorin Q1 Revenues Rise 34 Percent Despite Dip in COVID-19 Test Demand

Mar 17, 2022

DiaSorin Expects 2022 Revenue Growth From Base Business, Luminex as COVID-19 Testing Declines
Premium

Mar 16, 2022

DiaSorin 2021 Revenues Rise 41 Percent on SARS-CoV-2, Luminex Sales Growth

Feb 1, 2022

Genetic Analysis Receives CE Mark for Microbiome Test on Luminex Magpix Instrument

Nov 11, 2021

DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales

Sep 20, 2021

DiaSorin Molecular Receives CE Mark for Multiplex COVID-19, Influenza Test

Jul 30, 2021

DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand

May 14, 2021

DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand

Apr 13, 2021

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence
Premium

Apr 12, 2021

DiaSorin to Acquire Luminex for $1.8B

Feb 25, 2021

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.